8-K current report · filed Sep 1, 2026

NovoCure Ltd (NVCR) 8-K Current Report: September 1, 2026

Item 1.05Item 8.01NVCR overview

Short answer

NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 1.05 (Material Cybersecurity Incidents), Item 8.01 (Other Events). Standard forward-looking statement disclaimer covering clinical development, regulatory approvals, manufacturing, market prospects, and payer coverage.

  • This filing includes Item 1.05, an item that often signal trouble.

Why these 8-K items matter →

NovoCure Ltd 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.05 · Material Cybersecurity Incidents

  • Standard forward-looking statement disclaimer covering clinical development, regulatory approvals, manufacturing, market prospects, and payer coverage
  • Investor focus: execution and regulatory risks could materially affect Novocure’s future performance and financial results
  • Risk references include Novocure’s February 26, 2026 Form 10-K and subsequent SEC filings

Item 8.01 · Other Events

  • Mid-August 2026 cyberattack exposed data from over 1,400 U.S. patient records and fewer than 50 western U.S. patients
  • Exposed information included additional identifying data for fewer than 50 patients, plus provider and employee contact information
  • Medical treatment devices remained inaccessible, with operations and systems fully functional
  • Potential regulatory notifications, privacy claims and remediation costs remain under evaluation
  • NovoCure currently expects no material financial impact, but may amend the filing if that assessment changes

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other NovoCure Ltd 8-K filings

Get the next NVCR 8-K as it lands

Follow NVCR for push alerts, or ask the research agent what this filing means.